Adding Benign Breast Dz to Risk Model May Boost Preventive Care

This article originally appeared here.
Share this content:
Adding Benign Breast Dz to Risk Model May Boost Preventive Care
Adding Benign Breast Dz to Risk Model May Boost Preventive Care

THURSDAY, Sept. 24, 2015 (HealthDay News) -- Greater numbers of high-risk women eligible for primary prevention of breast cancer are identified by incorporating benign breast disease (BBD) diagnoses into the Breast Cancer Surveillance Consortium (BCSC) risk model, according to a study published online Aug. 17 in the Journal of Clinical Oncology.

Jeffrey A. Tice, M.D., from the University of California, San Francisco, and colleagues developed and validated a competing-risk model using 2000 to 2010 Surveillance, Epidemiology, and End Results data for breast cancer incidence and 2010 vital statistics to adjust for the competing risk of death.

The researchers found that of the 1,135,977 women (age 35 to 74 years) undergoing mammography with no history of breast cancer, 17 percent had a prior breast biopsy. Invasive breast cancer was diagnosed in 17,908 women over a mean follow-up of 6.9 years. Risk was slightly over-predicted using the BCSC BBD model (expected-to-observed ratio, 1.04) and had modest discriminatory accuracy (area under the receiver operator characteristic curve, 0.665). Adding BBD to the model increased the proportion of women with proliferative findings, with an estimated five-year risk of 3 percent or higher increasing from 9.3 to 27.8 percent (P < 0.001).

"Greater numbers of high-risk women eligible for primary prevention after BBD diagnosis are identified using the BCSC BBD model," the authors write.

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »